Compound K attenuates glucose intolerance and hepatic steatosis through AMPK-dependent pathways in type 2 diabetic OLETF rats
2
조회
0
다운로드
5
인용
0
참고문헌
키워드
초록
Background/Aims: Non-alcoholic fatty liver disease is associated with insulin resistance. Compound K (CK) is the final metabolite of panaxadiol ginsenosides that have been shown to exert antidiabetic effects. However, the molecular mechanism of the antidiabetic effects in the liver have not been elucidated; further, whether CK has beneficial effects in hepatosteatosis remains unclear. Therefore, we evaluated the effect of CK on hepatosteatosis as well as its mechanism in highfat diet (HFD)-fed type 2 diabetic Otsuka Long-Evans Tokushima Fatty (OLETF) rats. Methods: Twenty-four-week-old male OLETF rats were assigned to four groups: control (saline), CK 10 mg/kg, CK 25 mg/kg, or metformin 300 mg/kg (positive control); all treatments were administered orally for 12 weeks. Results: Fasting glucose levels of the CK25 group were significantly lower than those of the control group during the 12 weeks. The results of the oral glucose tolerance test showed that both the glucose concentration after glucose loading and the fasting insulin levels of the CK25 group were significantly lower than those of the control. Hepatosteatosis was significantly improved by CK25. CK25 and metformin significantly increased the phosphorylation of hepatic adenosine monophosphate-activated protein kinase (AMPK). CK25 significantly inhibited the expression of sterol regulatory element-binding protein-1c and fatty acid synthase, while upregulating that of peroxisome proliferator-activated receptor-α and carnitine palmitoyltransferase-1. Conclusions: CK improved glucose intolerance and hepatosteatosis in HFD-fed OLETF rats through AMPK activation, which has dual mode of action that involves decreasing the synthesis of fatty acids and increasing fatty acid oxidation.
Abstract
Background/Aims: Non-alcoholic fatty liver disease is associated with insulin resistance. Compound K (CK) is the final metabolite of panaxadiol ginsenosides that have been shown to exert antidiabetic effects. However, the molecular mechanism of the antidiabetic effects in the liver have not been elucidated; further, whether CK has beneficial effects in hepatosteatosis remains unclear. Therefore, we evaluated the effect of CK on hepatosteatosis as well as its mechanism in highfat diet (HFD)-fed type 2 diabetic Otsuka Long-Evans Tokushima Fatty (OLETF) rats. Methods: Twenty-four-week-old male OLETF rats were assigned to four groups: control (saline), CK 10 mg/kg, CK 25 mg/kg, or metformin 300 mg/kg (positive control); all treatments were administered orally for 12 weeks. Results: Fasting glucose levels of the CK25 group were significantly lower than those of the control group during the 12 weeks. The results of the oral glucose tolerance test showed that both the glucose concentration after glucose loading and the fasting insulin levels of the CK25 group were significantly lower than those of the control. Hepatosteatosis was significantly improved by CK25. CK25 and metformin significantly increased the phosphorylation of hepatic adenosine monophosphate-activated protein kinase (AMPK). CK25 significantly inhibited the expression of sterol regulatory element-binding protein-1c and fatty acid synthase, while upregulating that of peroxisome proliferator-activated receptor-α and carnitine palmitoyltransferase-1. Conclusions: CK improved glucose intolerance and hepatosteatosis in HFD-fed OLETF rats through AMPK activation, which has dual mode of action that involves decreasing the synthesis of fatty acids and increasing fatty acid oxidation.
참고문헌 (29)
- Bloom SR, "The obesity epidemic: pharmacological challenges", Mol Interv, 8, pp.82~98 (2008)[DOI]
- Wieckowska A, "Diagnosis of nonalcoholic fatty liver disease: invasive versus noninvasive", Semin Liver Dis, 28, pp.386~395 (2008)[DOI]
- Stein LL, "Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: current status", Adv Ther, 26, pp.893~907 (2009)[DOI]
- Ben Djoudi Ouadda A, "Increased hepatic lipogenesis in insulin resistance and type 2 diabetes is associated with AMPK signalling pathway up-regulation in Psammomys obesus", Biosci Rep, 29, pp.283~292 (2009)[DOI]
- Osler ME, "Adenosine 5'-monophosphate-activated protein kinase regulation of fatty acid oxidation in skeletal muscle", Endocrinology, 149, pp.935~941 (2008)[DOI]
- Lee SJ, "Induction of apoptosis by a novel intestinal metabolite of ginseng saponin via cytochrome c-mediated activation of caspase-3 protease", Biochem Pharmacol, 60, pp.677~685 (2000)[DOI]
- Yoon SH, "Anti-diabetic effects of compound K versus metformin versus compound K-metformin combination therapy in diabetic db", db mice, 2007, pp.30, 2196~2200
- Brunt EM, "Neuschwander- Tetri BA; NASH Clinical Research Network (CRN). Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings", Hepatology, 53, pp.810~820 (2011)[DOI]
- Adams LA, "A pilot trial of pentoxifylline in nonalcoholic steatohepatitis", Am J Gastroenterol, 99, pp.2365~2368 (2004)[DOI]
- Harrison SA, "A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients", Aliment Pharmacol Ther, 20, pp.623~628 (2004)[DOI]
- Lindor KD, "Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial", Hepatology, 39, pp.770~778 (2004)[DOI]
- Bugianesi E, "A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease", Am J Gastroenterol, 100, pp.1082~1090 (2005)[DOI]
- Belfort R, "A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis", N Engl J Med, 355, pp.2297~2307 (2006)[DOI]
- Ota T, "Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis", Gastroenterology, 132, pp.282~293 (2007)[DOI]
- Kita Y, "Metformin prevents and reverses inflammation in a non-diabetic mouse model of nonalcoholic steatohepatitis", PLoS One, 7, pp.e43056~ (2012)[DOI]
- 이진미, "GLP-1 Receptor Agonist and Non-Alcoholic Fatty Liver Disease", Diabetes and Metabolism Journal, 36(4), pp.262~267 (2012), 대한당뇨병학회[DOI]
- Park KG, "Alpha-lipoic acid decreases hepatic lipogenesis through adenosine monophosphate- activated protein kinase (AMPK)-dependent and AMPK-independent pathways", Hepatology, 48, pp.1477~1486 (2008)[DOI]
- Harrison SA, "Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis", Am J Gastroenterol, 98, pp.2485~2490 (2003)[DOI]
- Han GC, "Compound K enhances insulin secretion with beneficial metabolic effects in db", db mice, 2007, pp.55, 10641~10648
- Kim DY, "Compound K, intestinal metabolite of ginsenoside, attenuates hepatic lipid accumulation via AMPK activation in human hepatoma cells", J Agric Food Chem, 57, pp.1532~1537 (2009)[DOI]
- Kawano K, "OLETF (Otsuka Long-Evans Tokushima Fatty) rat: a new NIDDM rat strain", Diabetes Res Clin Pract, 24(Suppl), pp.S317~S320 (1994)[DOI]
- Steinberg GR, "AMPK in health and disease", Physiol Rev, 89, pp.1025~1078 (2009)[DOI]
- Viollet B, "Targeting the AMPK pathway for the treatment of type 2 diabetes", Front Biosci (Landmark Ed), 14, pp.3380~3400 (2009)
- Shimano H, "Sterol regulatory element-binding protein-1 as a dominant transcription factor for gene regulation of lipogenic enzymes in the liver", Trends Cardiovasc Med, 10, pp.275~278 (2000)[DOI]
- Shimano H, "Isoform 1c of sterol regulatory element binding protein is less active than isoform 1a in livers of transgenic mice and in cultured cells", J Clin Invest, 99, pp.846~854 (1997)[DOI]
- Clarke SD, "Regulation of fatty acid synthase gene expression: an approach for reducing fat accumulation", J Anim Sci, 71, pp.1957~1965 (1993)[DOI]
- Lee SK, "Coenzyme Q10 increases the fatty acid oxidation through AMPK-mediated <TEX>$PPAR{\alpha}$<", TEX>induction in 3T3-L1 preadipocytes, 2012, pp.24, 2329~2336
- Rao MS, "Peroxisomal beta-oxidation and steatohepatitis", Semin Liver Dis, 21, pp.43~55 (2001)[DOI]
- Foster DW, "The role of the carnitine system in human metabolism", Ann N Y Acad Sci, 1033, pp.1~16 (2004)[DOI]